Enlivex ENLV
NASDAQ ENLV
$0.39 -0.03 (-7.14%)
At close: Oct 2, 2026 · 4:00 PM EDT

Enlivex (ENLV) Gains from Sales and Divestitures (2024 - 2025)

Updated

Enlivex's Gains from Sales and Divestitures was $8,000 in Q4 2025, down 99.2% from $1.02 million a year earlier and down 60.0% from the prior quarter.

Analysis

Enlivex (ENLV) Gains from Sales and Divestitures (2024 - 2025) Analysis & Trends

For FY2025, Gains from Sales and Divestitures at Enlivex came in at $29,000, down 97.0% from FY2024.

  • In earlier years, Gains from Sales and Divestitures was $957,000 in FY2024 (-77.5%) and $4.24 million in FY2023.
  • Quarterly Gains from Sales and Divestitures has moved between -$66,000 (Q1 2024) and $1.02 million (Q4 2024) over five years.
  • Per Business Quant data, ENLV's Gains from Sales and Divestitures in the three quarters before Q4 2025 was $20,000 (Q3 2025), -$21,000 (Q2 2025) and $22,000 (Q1 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Enlivex 1.19 Mn -55.21 Mn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2025 8,000.00
Sep 30, 2025 20,000.00
Jun 30, 2025 -21,000.00
Mar 31, 2025 22,000.00
Dec 31, 2024 1.02 Mn
Mar 31, 2024 -66,000.00
API Access

Enlivex Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=ENLV&period=max&api_key=YOUR_API_KEY